Shl Telemedicine ( (CH:SHLTN) ) has shared an announcement.
On April 3, 2025, SHL Telemedicine announced the identification of several extraordinary non-recurring items during their 2024 financial review, which are expected to negatively impact their annual net profit and equity. These include a USD 13 million goodwill impairment related to German operations, adjustments of USD 3 million for intangible assets, and restructuring costs of approximately USD 3 million. The anticipated net loss ranges from USD 26 to 29 million, though the direct cash impact is limited to about USD 3 million. The final audited results for 2024 are expected by the end of April 2025.
More about Shl Telemedicine
SHL Telemedicine is a company focused on developing and marketing personal telemedicine systems and providing medical call center services, particularly targeting cardiovascular and related diseases. The company offers its services and devices to subscribers using telephonic and Internet communication technology, and is listed on both the SIX Swiss Exchange and the Nasdaq Stock Exchange.
Current Market Cap: CHF145.3M
See more data about SHLTN stock on TipRanks’ Stock Analysis page.